Inventor · disambiguated record
Paul Lyne
Also filed as: LYNE PAUL · LYNE PAUL D
11 granted patents·21 pending applications·86 citations·filing 2002–2017
90Inventor score
Top patents by PatentIndex Score
32 records- 0193US7358054B2Antibodies to VLA-1BIOGEN IDEC INC·Filed 2002·Granted Apr 15, 2008·37 cites·25 claims
- 0291US7910099B2Antibodies to VLA-1BIOGEN IDEC INC·Filed 2010·Granted Mar 22, 2011·12 cites·17 claims
- 0389US7723073B2Antibodies to VLA-1BIOGEN IDEC INC·Filed 2008·Granted May 25, 2010·10 cites·17 claims
- 0484US8084028B2Antibodies to VLA-1KARPUSAS MICHAEL·Filed 2011·Granted Dec 27, 2011·8 cites·21 claims
- 0581US7429644B2Humanized anti-LT-β-R antibodiesBIOGEN IDEC INC·Filed 2003·Granted Sep 30, 2008·9 cites·33 claims
- 0677US8324252B2Pyrazolylaminopyridine derivatives useful as kinase inhibitorsDAVIES AUDREY·Filed 2006·Granted Dec 4, 2012·3 cites·3 claims
- 0776US10336826B2Antibodies to VLA-1BIOGEN MA INC·Filed 2017·Granted Jul 2, 2019·1 cites·15 claims
- 0869US7691865B2Pyrazolopyridines and methods of making and using the sameBIOGEN IDEC INC·Filed 2003·Granted Apr 6, 2010·5 cites·11 claims
- 0961US7423061B2Substitute thiophenes and uses thereofASTRAZENECA AB·Filed 2004·Granted Sep 9, 2008·1 cites·17 claims
- 1061US2009054396A1Substituted thiophenes and uses thereofASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 1159US2009092601A1HUMANIZED ANTI-LT-beta-R ANTIBODIESBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 1256US9644030B2Antibodies to VLA-1BIOGEN MA INC·Filed 2015·Granted May 9, 2017·0 cites·21 claims
- 1355US2012177638A1Antibodies to vla-1KARPUSAS MICHAEL·Filed 2011·Application pending·0 cites
- 1451US8835465B2Pyrazolylaminopyridine derivatives useful as kinase inhibitorsASTRAZENECA AB·Filed 2012·Granted Sep 16, 2014·0 cites·17 claims
- 1551US2010105714A1Furanone Compounds and Methods of Making and Using The SameBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 1648US2007010556A1Thiophene derivatives as chk 1 inhibitorsASTRAZENECA AB·Filed 2004·Application pending·0 cites
- 1747US2010216791A1Pyridinylquinazolinamine derivatives and their use as b-raf inhibitorsASTRAZENECA·Filed 2007·Application pending·0 cites
- 1846US2010029643A1Heterocyclyc sulfonamides having edg-1 antagonistic activityASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 1943US2008312206A1Chemical Compounds-149ASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 2043US2009170849A1Quinazolinone derivatives having b-raf inhibitory activityASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 2143US2009149484A1Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing themASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 2242US2008207616A1Quinoxalines as B Baf InhhibitorsASTRAZENECA AB·Filed 2005·Application pending·0 cites
- 2342US2009227648A1Pyrazole derivatives useful for the treatment of cancerASTRAZENECA AB·Filed 2005·Application pending·0 cites
- 2442US2007149560A1Novel fused triazolones and the uses thereofASTRAZENECA AB·Filed 2004·Application pending·0 cites
- 2541US2008306096A1Quinazoline Derivatives, Process for Their Preparation and Their Use as Anti-Cancer AgentsASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 2641US2009275570A1Substituted heterocycles and their use as chk1, pdk1 and pak inhibitorsASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 2740US2007259849A1Azine-Carboxamides as Anti-Cancer AgentsASTRAZENECA AB·Filed 2005·Application pending·0 cites
- 2839US2009163525A1Substituted quinazolines with anti-cancer activityASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 2939US2009118261A1Quinazolinone derivatives and their use as b-raf inhibitorsASTRAZENECA AB·Filed 2005·Application pending·0 cites
- 3038US2008275022A1Substituted Quinazolones as Anti-Cancer AgentsASTRAZENECA AB·Filed 2005·Application pending·0 cites
- 3137US2008146570A1Chemical CompoundsASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 3236US2009054469A1Quinazolinone derivatives and their use as b-raf inhibitorsASTRAZENECA AB·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →